18 June 18-21, 2015 Starting at 8:00am
Victoria, BC Victoria Conference Centre
Register Now »

Retina


Canadian Retina Society

Clinical update: Retina

Friday, June 19, 1330-1500
Carson A

OBJECTIVES

At the end of this session, participants will be able to:

  • Have a better understanding of OCT angiography
  • Understand current treatment recommendations for VMA and RVO
  • Identify current uses for genetic testing in ophthalmology

GUESTS

Lee Jampol
David Sarraf
Alan Cruess
David Chow
Alex Levin

MODERATORS

James Whelan
Murray Erasmus

Schedule

1330 Introduction · James Whelan, President CRS
1335 Treatment of diabetic macular edema Protocols I and T · Lee Jampol
1350 Discussion
1355 OCT angiography of type 1 versus type 3 neovascularization in AMD · David Sarraf
1410 Discussion
1415 Evolving management of patients with symptomatic VMA · David Chow
1430 Discussion
1435 Optimal treatment of retinal vein occlusion: Canadian expert consensus · Alan Cruess
1445 Is genetic testing ready for prime time? · Alex Levin

1455 Panel discussion · All speakers

Canadian Retina Society

Retina I

Friday, June 19, 1545-1715
Carson A

OBJECTIVES

At the end of this session, participants will be able to:

  • Understand a technique for sutureless IOL fixation
  • Gain an understanding of the use of ocriplasmin in VMA/VMT
  • Be aware of importance of face down positioning and a technique for approaching chronic persistent macular holes

GUESTS

Lee Jampol
Warren Hill

MODERATORS

James Whelan
Netan Choudhry

Schedule

1545 Introduction · Netan Choudhry
1550 150 years of retina Lee Jampol
1620 Discussion
1630 Initial outcomes following intravitreal ocriplasmin for the treatment of symptomatic vitreomacular adhesion: A Canada-wide study · N. Choudhry, M. Brent, R. Dookeran, D. Dhanda M. Fielden, M.A. Kapusta, J. Noble, D. Lederer
1625 Discussion
1627 Investigation of vitreous levels of atorvastatin in patients requiring vitrectomies · C.L. Wendel, K. Ramsey, P. Hopp, K. Donkor
1632 Discussion
1634 Sutureless intraocular lens implantation using microvitreoretinal blade beveled sclerotomies · C. Ryu, J.C. Chen
1639 Discussion
1641 Spectral domain optical coherence tomography-guided face down posturing versus 1 week face down posturing after idiopathic full-thickness macular hole surgery · K. Xu, E. Navajas
1646 Discussion
1648 Subretinal BSS injection: A technique for the treatment of chronic persistent macular holes · A. Szigiato, F. Gilani, M.K. Walsh, R. Muni
1653 Discussion
1655 Assessment of anatomical and functional outcomes in the Ocriplasmin for Vitreomacular Traction Intravitreal Injection Decisions (OVIID 1) Trial · D.R. Chow
1700 Discussion
1702 IOL power selection in the setting of vitreoretinal disorders · Warren Hill

Canadian Retina Society

Retina II

Saturday, June 20, 1330-1545
Carson A

OBJECTIVES

At the end of this session, participants will be able to:

  • Understand the spectrum of retinal toxicity with multimodal analysis
  • Be aware that changes in intraocular cytokine levels following IVB and IVR have been reported. Understanding the role of these intraocular cytokines could be important in helping improve treatment of these diseases
  • Identify whether the fibrovascular scar location on spectral-domain optical coherence tomography (SD OCT) is predictive of visual acuity outcome in an eye after successful treatment with anti-VEGF agents

GUEST

David Sarraf

MODERATORS

Netan Choudhry
Murray Erasmus

Schedule

1330 Introduction
Murray Erasmus
1335 Spectrum of retinal toxicity with multimodal analysis · David Sarraf
1405 Discussion
1410 A randomized double-masked study evaluating changes in intraocular cytokine levels following intravitreal bevacizumab and ranibizumab · C. Or, P.J. Kertes, K.T. Eng, D.A. Albiani, A. Kirker, A.B. Merkur, N. Fallah, S. Cao, J. Cui, J.A. Matsubara, F. Forooghian
1415 Discussion
1417 Baseline characteristics and visual acuity outcomes of Canadian patients in AURA · A.R. Berger, R.G. Devenyi, D. Maberley, T. Sheidow, E. Tourville, L. Brunck
1422 Discussion
1424 Correlation of visual acuity with fibrotic scar location in macular degeneration eyes treated with anti-VEGF agent · C. Ryu, S. Al-Humaid, E. Rampakakis, J. Galic, J.C. Chen
1429 Discussion
1431 A Canadian registry of ranibizumab in neovascular age-related macular degeneration: effectiveness and safety outcomes from the LENS study · M. Giunta, P. Saurel, A. Courseau
1436 Discussion
1438 Interim analysis of a 12-month, exploratory, open-label study of aflibercept in retinal pigment epithelial detachments secondary to neovascular age-related macular degeneration · B. Li, L. Pal, J. Gonder
1443 Discussion
1445 Approaching Chinese with AMD outside Asia: Is PCV recognized and treated appropriately? · Y.N. Chen, R.G. Devenyi, M. Brent, P.J. Kertes, K.T. Eng, R. Kohly, C. Schwartz, D. Wong, A.R. Berger, D. Chow, F. Altomare, L. Giavedoni, R. Muni, Y. Jin, A. K. Soon, P. Yoo, W. Lam
1450 Discussion

Canadian Retina Society

Retina III

Saturday, June 20, 1545-1715
Carson A

OBJECTIVES

At the end of this session, participants will be able to:

  • Appreciate the use of multimodal imaging in white spot syndromes
  • Identify deep retinal capillary ischemia using OCT angiography
  • Utilize of combination therapy of anti-vascular endothelial growth factor (anti-VEGF) plus grid laser in the management of macular edema secondary to branch retinal vein occlusion (BRVO)

GUEST

Lee Jampol
David Sarraf

MODERATORS

James Whelan
Netan Choudhry

Schedule

1545 Introduction · James Whelan
1550 Multimodal imaging of white spot syndromes · Lee Jampol
1605 Discussion
1610 OCT angiography of deep retinal capillary ischemia · David Sarraf
1625 Discussion
1630 Is a specific defensin gene profile associated with endophthalmitis following a variety of intraocular procedures? · J. Park, W. Lam, R.G. Devenyi, P.J. Kertes, J. Kwok, E. Carreno-Salas, R. Haynes, A. Churchill, N. Crama, J. Zarranz-Ventura
1635 Discussion
1637 Baseline characteristics of Canadian patients with wet AMD (nAMD), diabetic macular edema (DME) and retinal venous occlusion (RVO) enrolled in the LUMINOUS study · T. Sheidow
1642 Discussion
1644 Sensitivity and specificity of multifocal ERG in detection of chloroquine and hydroxychloroquine toxicity · S.G. Coupland, S. Ahmadi, C. Gottlieb, J. Hamilton
1649 Discussion
1652 Changes in retinal blood flow and oxygenation parameters in response to an intravitreal injection of ranibizumab in patients with retinal vein occlusion · D. Carlone, S. Joshi, L. Khuu, C. Hudson, W. Lam
1657 Discussion